Content Conference Coverage Conferences DDW 2014
DDW 2014: Some Hepatitis B Patients Can Stop Antiviral Treatment without Relapse
- Details
- Category: HBV Treatment
- Created on Tuesday, 06 May 2014 00:00
Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.
DDW 2014: Sustained Response to Interferon Is Durable in Children with Hepatitis C
- Details
- Category: HCV Treatment
- Created on Wednesday, 21 May 2014 00:00
Children with hepatitis C treated with interferon-based therapy continued to show undetectable HCV viral load up to 7 years after achieving sustained virological response in the PEDS-C trial, researchers reported at Digestive Disease Week this month in Chicago.
DDW 2014: AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Created on Monday, 12 May 2014 00:00
AbbVie's all-oral "3D" regimen containing ABT-450, ombitasvir, and dasabuvir, used with or without ribavirin, led to sustained virological response in 90% to 100% of genotype 1a and 1b hepatitis C patients in the Phase 3 PEARL trials, according to data reported at the Digestive Disease Week (DDW 2014) meeting last week in Chicago and in the May 4 online edition of the New England Journal of Medicine.
DDW 2014: Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
- Details
- Category: Experimental HCV Drugs
- Created on Sunday, 18 May 2014 00:00
Some factors traditionally associated with poorer response to interferon-based therapy for hepatitis C played little role in clinical trials of the HCV protease inhibitor faldaprevir, according to several studies presented at Digestive Disease Week this month in Chicago. HCV subtype 1a and prior treatment did not significantly worsen response, while HIV/HCV coinfection may be associated with better response.
New Hepatitis C Treatments Highlighted at Digestive Disease Week
- Details
- Category: Experimental HCV Drugs
- Created on Tuesday, 06 May 2014 00:00
Direct-acting antiviral agents for hepatitis C were a key theme of Digestive Disease Week 2014, taking place this week in Chicago. While the conference covers all aspects of gastroenterology and hepatology, new treatments that can cure more than 90% of chronic hepatitis C patients with few side effects in as little as 8 to 12 weeks are bringing about a revolution in the field.
Web Design and Development by